← UNITED THERAPEUTICS Corp UTHR
Market Price
$499.71
Market Cap
$21.30B
P/E Ratio
17.94
Revenue (FY 2025)
↑10.6% YoY
$3.18B
3-Yr CAGR: 18.0%
Net Income
↑11.7% YoY
$1.33B
Net Margin: 41.9%
Free Cash Flow
↓-3.7% YoY
$1.04B
FCF Yield: 4.89%
EPS (Diluted)
↑13.1% YoY
$27.86
Basic: $30.13
Return on Equity
Efficiency
18.8%
ROA: 36.0%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (UTHR)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $1,598.8M | — | $1,526.1M | $713.7M | — | $15.25 | — | $643.6M | $605.6M | — |
| FY 2017 | $1,725.3M | +7.9% | $1,619.6M | $417.9M | -41.4% | $9.31 | -39.0% | $474.2M | $387.9M | -35.9% |
| FY 2018 | $1,627.8M | -5.7% | $1,429.1M | $589.2M | +41.0% | $13.39 | +43.8% | $778.4M | $594.0M | +53.1% |
| FY 2019 | $1,448.8M | -11.0% | $1,331.2M | $-104.5M | -117.7% | $-2.39 | -117.8% | $-206.6M | $-290.3M | -148.9% |
| FY 2020 | $1,483.3M | +2.4% | $1,375.2M | $514.8M | +592.6% | $11.54 | +582.8% | $755.7M | $696.4M | +339.9% |
| FY 2021 | $1,685.5M | +13.6% | $1,563.0M | $475.8M | -7.6% | $10.06 | -12.8% | $598.2M | $477.4M | -31.4% |
| FY 2022 | $1,936.3M | +14.9% | $1,784.7M | $727.3M | +52.9% | $15.00 | +49.1% | $802.5M | $663.7M | +39.0% |
| FY 2023 | $2,327.5M | +20.2% | $2,070.0M | $984.8M | +35.4% | $19.81 | +32.1% | $978.0M | $747.6M | +12.6% |
| FY 2024 | $2,877.4M | +23.6% | $2,567.7M | $1,195.1M | +21.4% | $24.64 | +24.4% | $1,327.1M | $1,080.6M | +44.5% |
| FY 2025 | $3,182.7M | +10.6% | $2,798.3M | $1,334.7M | +11.7% | $27.86 | +13.1% | $1,561.2M | $1,040.7M | -3.7% |
Valuation
Market Price
$499.71
Market Cap
$21.30B
Enterprise Value
N/A
P/E Ratio
17.94
P/B Ratio
2.99
FCF Yield
4.89%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
87.92%
Operating Margin
46.89%
Net Margin
41.94%
Return on Equity (ROE)
18.81%
Return on Assets (ROA)
36.05%
Asset Turnover
0.86x
Revenue 3-Yr CAGR
18.02%
Financial Health & Liquidity
Current Ratio
7.70
Cash Ratio
3.24
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$1.56B
Total Debt
N/A
Book Value / Share
$167.18
Cash Flow Efficiency
Operating Cash Flow
$1.56B
Capital Expenditures (CapEx)
$520.50M
Free Cash Flow
$1.04B
OCF / Revenue
49.05%
FCF / Revenue
32.70%
FCF 3-Yr CAGR
16.18%
Per Share Metrics
EPS (Diluted)
$27.86
EPS (Basic)
$30.13
Dividends / Share
N/A
Book Value / Share
$167.18
EPS YoY Growth
13.07%
Balance Sheet (FY 2025)
Total Assets
$3.70B
Total Liabilities
$480.90M
Stockholders' Equity
$7.10B
Current Assets
$3.70B
Current Liabilities
$480.90M